Edwards Lifesciences Corporation (ETR:EWL)

-16.93% (1Y)

Market Cap	39.93B
Revenue (ttm)	5.11B
Net Income (ttm)	3.87B
Shares Out	n/a
EPS (ttm)	6.50
PE Ratio	10.32
Forward PE	31.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85
Average Volume	55
Open	67.91
Previous Close	67.86
Day's Range	66.60 - 67.91
52-Week Range	54.00 - 87.12
Beta	n/a
RSI	48.43
Earnings Date	Jul 23, 2025

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solution...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 1958
• Employees: 15,800
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: EWL

Financial Performance

In 2024, Edwards Lifesciences's revenue was $5.44 billion, an increase of 8.57% compared to the previous year's $5.01 billion. Earnings were $4.17 billion, an increase of 197.68%.

Financial numbers in USD